<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549272</url>
  </required_header>
  <id_info>
    <org_study_id>LMB08</org_study_id>
    <nct_id>NCT04549272</nct_id>
  </id_info>
  <brief_title>Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale</brief_title>
  <official_title>Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patent foramen ovale arises from the incomplete postnatal fusion of the septum primum and&#xD;
      secundum and can cause paradoxical embolism in adults. In case of cerebral ischemic stroke,&#xD;
      the correlation with the patent foramen ovale is based on probabilistic approach. For this&#xD;
      reason, continuous research is indispensable, especially according to new approaches, to&#xD;
      offer tools capable of guiding in case of adverse event with greater certainty and even&#xD;
      better to prevent it. Thus, this study aims to: 1) evaluate the microstructural brain damage&#xD;
      through advanced MRI analysis in patients with patent foramen ovale; 2) evaluate how much the&#xD;
      degree of the shunt can affect brain damage. In order to do this, this study aims to evaluate&#xD;
      advanced brain imaging in a cohort of patients with patent foramen ovale to identify the&#xD;
      development of early vascular damage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of percentage change in diffusion parameters of the white matter</measure>
    <time_frame>At Enrollment</time_frame>
    <description>Fiber tracking by DTI MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of the degree of shunt of the patent foramen ovale</measure>
    <time_frame>At Enrollment</time_frame>
    <description>Echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of cognitive decline by decrease of MoCA score</measure>
    <time_frame>At Enrollment</time_frame>
    <description>Cognitive tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of a non-invasive retinal screening</measure>
    <time_frame>At Enrollment</time_frame>
    <description>Digital ophthalmoscope</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Patients with Patent Foramen Ovale</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <description>No interventions - observational study</description>
    <arm_group_label>Patients with Patent Foramen Ovale</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from patients attending the Department of AngioCardioNeurology of&#xD;
        the IRCCS Neuromed, accordingly to the following inclusion/exclusion criteria.&#xD;
        Approximately 100 subjects of both genders will be included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 and ≤ 65 years&#xD;
&#xD;
          -  patients with patent foramen ovale&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous IMA, stroke or TIA&#xD;
&#xD;
          -  arrhythmia or severe cardiac disease&#xD;
&#xD;
          -  hypertension, diabetes or renal disease&#xD;
&#xD;
          -  psychiatric disease&#xD;
&#xD;
          -  neurological or neurodegenerative disease&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  assumption of drugs known to interfere with cognitive function&#xD;
&#xD;
          -  inability to be subjected MRI analysis&#xD;
&#xD;
          -  participation to other clinical trial, ongoing or terminated less than one month&#xD;
             before enrolment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Lembo, MD, PhD</last_name>
    <phone>+390865915225</phone>
    <email>lembo@neuromed.it</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Giuseppe Lembo</investigator_full_name>
    <investigator_title>Full Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Vascular Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

